Vanflyta to treat myeloid leukemia
Name: Vanflyta Indications: To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria. Active Ingredient: Quizartinib Company: Daiichi Sankyo, Inc Approval Date:…
CYFENDUS vaccine for prophylaxis following exposure to Bacillus anthracis
Tradename: CYFENDUS Proper Name: Anthrax Vaccine Adsorbed, Adjuvanted Indication: Indicated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of…
DENGVAXIA vaccine for prevention of dengue disease caused by dengue virus
Tradename: DENGVAXIA Proper Name: Dengue Tetravalent Vaccine, Live Indication: To include safety and efficacy data that support the use of DENGVAXIA in individuals 6 through 16 years of age with…
ROCTAVIAN a virus vector-based gene therapy for hemophilia A
Tradename: ROCTAVIAN Proper Name: valoctocogene roxaparvovec-rvox Indication: Valoctocogene roxaparvovec-rvox is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency…
Ngenla to treat growth failure
Drug Name: Ngenla Indications: To treat growth failure due to inadequate secretion of endogenous growth hormone. Active Ingredient: Somatrogon-ghla Company: Pfizer Inc, OPKO Health Inc Approval Date: 6/27/2023 More…
LANTIDRA for the treatment of adults with Type 1 diabetes
Tradename: LANTIDRA Proper Name: donislecel-jujn Indication: Indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe…
Rystiggo to treat myasthenia gravis
Drug Name: Rystiggo Indications: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive. Active Ingredient: Rozanolixizumab-noli Company: UCB, Inc Approval Date: 6/26/2023 More…
Litfulo to treat hair loss
Name: Litfulo Indications: To treat severely patchy hair loss. Active Ingredient: Ritlecitinib Company: Pfizer Labs Approval Date: 6/23/2023 More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf
ELEVIDYS for treatment of Duchenne muscular dystrophy
Tradename: ELEVIDYS Proper Name: delandistrogene moxeparvovec-rokl Indication: Indicated for treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the…
Columvi to treat B-cell lymphoma
Drug Name: Columvi Indications: To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy. Active…